ELI LILLY & CO

FDA removes suicide‑risk warning from Eli Lilly’s GLP‑1 weight‑loss drugs, simplifying prescribing, boosting patient confidence, and strengthening brand trust.

Explore how Eli Lilly’s $1.1 B acquisition of Ventyx Biosciences and new analyst upgrades boost its pipeline, diversify revenue, and position the pharma giant for growth in oral inflammatory therapies.

Read how Eli Lilly’s 10‑% price cut on Mounjaro and Zepbound could boost Chinese obesity market share, drive reimbursement, and add ¥2.8 billion in NPV.

Explore how Eli Lilly’s expanding weight‑loss portfolio is reshaping investor sentiment, valuation and market dynamics amid GLP‑1 litigation and growth trends.

Explore Eli Lilly’s obesity strategy: proven sales of Mounjaro & Saxenda plus breakthrough Retatrutide data showing 17.5% weight loss—what this means for investors and future growth.

Explore Eli Lilly’s soaring $1T market cap, GLP‑1 revenue growth, and Medicare pricing risks—insights that help investors gauge its long‑term value.

How Eli Lilly’s $1T milestone and GLP‑1 drugs Mounjaro & Zepbound are reshaping weight‑loss treatment and driving market growth.

Discover how Eli Lilly’s GLP‑1 platform and dual‑agonist pipeline propelled its market cap beyond $1 trillion, reshaping obesity therapy and investor confidence.

Explore Eli Lilly’s 126.6% revenue surge, fueled by Mounjaro and Zepbound, and why its diversified pipeline keeps the pharma stock poised for growth amid fierce competition and macro risks.

Eli Lilly’s stock price has surged by nearly 6% after its weight-loss medication, Orforglipron, met its primary goals in a Phase 3 trial, bringing it closer to regulatory approval.